4 results
Correcting or preventing deficiencies of protein, by means of a protein supplement after a biliopancreatic diversion.
The primary objective of this study is to assess if clinically relevant changes occur in fat free mass (FFM) between baseline and follow up six months after the end of treatment. Our cut-off value of a clinically relevant difference in body…
Primary objective: To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants<3rd percentile * born at 26-32 weeks GA. * According to Fenton preterm growth chart. Secondary…
The primary objective is to evaluate the efficacy and safety of NTRA-9620 compared with placebo when added to standard of care (SOC) in pediatric subjects (aged 28 weeks post-menstrual age to 52 weeks chronological age) with SBS within 4 months from…